Capricor Therapeutics (CAPR) Tops Q2 EPS by 6c

Capricor Therapeutics (NASDAQ: CAPR) reported Q2 EPS of ($0.29), $0.06 better than the analyst estimate of ($0.35). Revenue for the quarter came in at $3.92 million versus the consensus estimate of $3 million.

For earnings history and earnings-related data on Capricor Therapeutics (CAPR) click here.

You May Also Be Interested In

• SanDisk and Micron surge as Apple confirms memory price pass-through
• Air France-KLM (AF:FP) (AFLYY) PT Raised to EUR13.50 at UBS
• Pfizer reafffirms 2026 guidance after CFO transition announcement